BridgeBio (BBIO) Tumbles 15%, Mirrors Marked Bleed

Core Viewpoint - BridgeBio Pharma Inc. (NASDAQ:BBIO) experienced a significant decline of 15.24% on Thursday, closing at $63.73, reflecting broader market pessimism and portfolio repositioning ahead of its earnings report [1][3]. Company Performance - The stock's drop was influenced by negative market sentiment, particularly following a 50% decline in Bitcoin from its all-time high of $126,000, compounded by Treasury Secretary Scott Bessent's comments regarding the lack of authority to bail out cryptocurrencies [3]. - BridgeBio is scheduled to release its financial and operational highlights for Q4 and full-year 2025 on February 19, 2026 [2]. Analyst Ratings - Barclays and Morgan Stanley have issued an "overweight" rating for BridgeBio, with Barclays setting a price target of $157, indicating a potential upside of 146% from the latest closing price, while Morgan Stanley's target of $96 suggests a 50.6% upside [4].